BACKGROUND: Access to glycosylated hemoglobin (HbA1c) assays in clinical practice remains limited. We investigated the relationship of fasting plasma glucose and HbA1c to determine optimal glucose levels for pre--dicting HbA1c.
B oth the Diabetes Control and Complications Trial (DCCT)
1 and the United Kingdom Prospective Diabetes Study (UKPDS) 2 have demonstrated unequivocally that tight control of blood glucose can significantly reduce progression of comp p plications in both type 1 and type 2 diabetes mellitus. Glycosylated hemoglobin (HbA1c) has been used as a "gold standard" for mean glycemia and as a meap p sure of risk for the development of diabetesprelated complications. 3, 4 The American Diabetes Association (ADA) suggested HbA1c levels less than 7% as a goal for optimal glycemic control, 5 while the American Association of Clinical Endocrinology (AACE) 6 and the International Diabetes Federation (IDF) set a lower target (6.5% or less). 7 The ADA recommends that HbA1c be tested 2 to 4 times annually, based on the patient' s glycemic control.
The utility of fasting plasma glucose in predicting glycosylated hemoglobin in type 2 diabetes
However, several barriers to HbA1c testing have been identified at the primary and managed care level, 8p10 inp p cluding physicians' and patients' awareness and the relap p tive cost of the test. In this study we aimed to determine the relationship of fasting plasma glucose (FPG) meap p surements obtained routinely in primary health care outpatient clinics to simultaneously measured HbA1c levels. We also investigated optimal FPG levels which best predict HbA1c ≥7.0% or >6.5% to guide physip p cians in intensifying antidiabetic therapy.
SUBJECTS AND METHODS
We retrospectively analyzed the data of 2888 patients with type 2 diabetes mellitus, aged 20 years or older, atp p tending minipdiabetes clinics at 21 of 24 primary health care centers, in the capital, Muscat (Oman). These centers cover a population of over 600 000 and nearly 8000 diabetic patients are on their National Diabetes Registers. About 14% of patients had their HbA1c tested more than once during the study period, and were included in the analysis, giving the total number of 3359. Patients with missing data were excluded from the analysis. The study included patients attending over the period from July 2003 to June 2004.
Venous blood samples were collected in tubes conp p taining ethylenediaminetetraacetic acid (EDTA), lap p beled and transferred in cold boxes filled with ice to a tertiary hospital laboratory. There, samples were stored at 2 to 8ºC as recommended by the manufacturer for analysis on every Monday of the week. Samples were analyzed using Roche/Hitachi 902 instruments (Boehringer Mannheim, Tokyo, Japan). According to the manufacturer, HbA1c determination in this instrup p ment is based on turbid metric inhibition immunoasp p say for hemolyzed whole blood and uses the detergent tetradecyltrimetylammonium bromide (TTAB) as the hemolysing reagent to eliminate interference from leup p kocytes. All hemoglobin variants that are glycated at the Npterminal of the Bpchain and have antibody recognizp p able regions identical to that of HbA1c are determined by the assay. Reagents and calibration kits were supp p plied by the same manufacturer. Prior to analysis of evp p ery batch, the instrument was checked for calibration.
Plasmapcalibrated fasting blood glucose was deterp p mined in primary health centers using One Touch II ( Johnson & Johnson) glucose meters. On every request for analysis of HbA1c, primary care physicians were rep p quired to state the fasting capillary blood glucose level that was determined on the same day of venous blood collection for HbA1c. A linear regression analysis was performed to study the relationship between FPG and HbA1c using Stata (version 9.1, Stata Corporation, TX, USA). Receiverp operating characteristic (ROC) curves were generp p ated to determine optimal FPG cutppoints predicting HbA1c ≥7.0% and >6.5%, using MedCalc (version9), which also calculates the area under the curve (AUC), sensitivity, specificity, likelihood ratio and positive prep p dictive values with 95% confidence intervals (CI). The larger the AUC the more accurate the test; an associp p ated Ppvalue <0.05 was considered statistically signifip p cant. Unlike predictive values, likelihood ratios are not affected by the prevalence of the attribute and can be used to summarize how many times a subject with a specified FPG cutppoint is more (or less) likely to have HbA1c ≥7.0% (or >6.5%) than a subject without that FPG value. For any test, likelihood ratios above 1 inp p crease the probability that the "disorder" is present (in this case HbA1c ≥7.0% or >6.5%), and likelihood ratios <1 decrease the probability that the "disorder" is present.
11 Permission to conduct the study was obp p tained from the research and ethical committee within the Ministry of Health.
RESULTS
The mean age (SD) of the 2888 patients was 52 (11.6) years. In many diabetes clinics in developing countries, HbA1c may not always be available for the clinician to permit therapy adjustment. For example, in two univerp p sity teaching hospitals, only 40% and 50% of patients had HbA1c registered on their medical records within the previous year. 13, 14 On the other hand, FPG is often routinely measured in diabetes clinics for all patients prior to consultation with the physician. Thus the utilp p ity of FPG would increase if the physician can use this value to predict the glycemic index of the patient with diabetes in an outpatient setting. Our study provides specific FPG cutppoints that may be used to guide clinical decisions to intensify antidiabetic therapy in the absence of HbA1c or home glucose monitoring values. Nearly twopthirds (64.5%) of our patients with FPG >9.0 mmol/L were correctly identified to have HbA1c ≥7.0% while FPG >8.2 mmol/L identified nearly threep quarter (72%) of those with HbA1c >6.5%.
Rohlfing et al, in their analysis of glucose profiles and HbA1c of the DCCT, found that an FPG of 9.5 mmol/ L corresponded to an HbA1c of 7%, and 7.5 mmol/L corresponded to 6%. 15 ElpKebbi et al 16 reported that an FPG >9.2 mmol/L best predicted HbA1c >8.0% in a population of African Americans, with a sensitivity of 80% and specificity of 83%. When casual postpranp p dial plasma glucose was used, a lower cutppoint (8.3 mmol/L) was reported to predict both HbA1c >6.5% or ≥7.0%.
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Although many studies have used statistical methp p ods to predict HbA1c from FPG, the validity of this approach in assessing glycemic control in patients with diabetes has been questioned. 18 Bouma et al 19 showed in 1020 patients with type 2 diabetes that HbA1c is difficult to predict from FPG values: only 66% of the patients with HbA1c <7.0% were identified by FPG values <7.8 mmol/L. They concluded that predicting HbA1c changes from FPG changes is even more diffip p cult. Similarly, Avignon et al, 20 demonstrated in 66 type 2 diabetic patients that early postplunch (2:00 pm) and extended postplunch (5:00 pm) plasma glucose correp p lated significantly and independently with HbA1c, but that of prepbreakfast and preplunch plasma glucose did not. Nonetheless, the ADA states that "FPG is somep p what better than postpprandial glucose in predicting HbA1c, especially in type 2 diabetes". 21 Other studies have shown that, in such patients, fasting blood glup p cose determinations (at intervals of weeks to months) provide a better measure of longpterm glycemia than in patients with type 1 diabetes.
22,23
In addition to the statistical methods used to estip p mate longpterm glycemic control, standard methods such as selfpmonitoring of blood glucose, venous blood glucose and HbA1c remain the main stay of diabetes care to achieve a specific level of glycemic control and to prevent hypoglycemia. Physicians ought to use stanp p dard methods of investigation when providing diabetes care and encouraging patients to perform selfpmonitorp p ing blood glucose measurements as needed.
This study documents for the first time that the map p jority of patients (76%) with type 2 diabetes in primary care in Oman exhibit poor glycemic control (HbA1c ≥7.0%) according to the ADA guidelines. 5 The prevp p alence of poor control increases to 82% if the AACE target is applied (HbA1c >6.5%). These results are consistent with two studies from Saudi Arabia and one from Lebanon where poor control was prevalent among 73%, 77%, and 72% of patients with diabetes, respecp p tively. 13, 14, 24 In comparison, two National Health and Nutrition Examination Surveys, conducted between the periods 1988p1994 and 1999p2000 in the US, rep p ported that 56% and 63% patients had poor glycemic control, respectively. 25 Higher rates of poor control were reported from other studies among African Americans (77%) and Finnish people (75%). 17, 26 This clearly highp p lights the urgent need for intervention to improve diap p betes care in developing and developed countries. Our study has some limitations. First, adopting an FPG cutppoint of >9.0 mmol/L as a predictor of HbA1c ≥7.0% would result in about 35.5% of individp p uals being "missed" as they will be considered to have good glycemic control when in fact they do not (false negative). Similarly, 17.3% of people may be at risk of hypoglycemia as they may be subjected to more intense antipdiabetic therapy when in fact having good glycep p mic control (false positive). Nonetheless, hypoglycemia tends to be uncommon and mild in patients with type 2 diabetes, even in settings in which intensive diabep p tes therapy is guided by treatment algorithms based on glucose levels obtained during office visits. 27 In addip p tion, in the presence of high levels of poor control (as is the case in many settings), hypoglycemia may not be a common complication.
The above relation between FPG and HbA1c was derived without adjustment for other confounders like age, gender, body mass index, smoking status, type and duration of diabetes. Including such variables may rep p sult in more accurate cutppoints, yet it would have compromised the objective of this study, which was to increase the utility of FPG in clinical practice by makp p ing it simple.
Finally, the accuracy of glucose measurement instrup p ments used in primary care during the study period was not evaluated by simultaneous matched measurement of venous blood samples. However, several studies have demonstrated a high degree of accuracy of such instrup p ments when compared with the laboratory reference over a broad range of glucose concentrations.
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In conclusion, we have identified a cutppoint for FPG that may be used as an indicator of glycemic control in patients with type 2 diabetes when current HbA1c levp p els or home blood glucose monitoring records are not available. 
